Form 4: Niagen Bioscience CFO Boosts Stake in Company
Insider Transaction Report
Niagen Bioscience's CFO, Ozan Pamir, acquired common stock directly and indirectly through a pre-arranged trading plan.
Summary
- Chief Financial Officer Ozan Pamir acquired 4,464.962 shares of Niagen Bioscience common stock directly at a weighted average price of $6.81 per share on November 14, 2025.
- An additional 2,220.443 shares were acquired indirectly by Pamir's spouse at $6.85 per share on the same date.
- The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
- Following these transactions, Pamir directly beneficially owns 7,372.159 shares and indirectly owns 2,220.443 shares.
Sentiment
Score: 7
Explanation: The purchase of company stock by a Chief Financial Officer, especially under a 10b5-1 plan, generally indicates management's confidence in the company's future prospects and valuation.
Positives
- CFO Ozan Pamir increased his beneficial ownership in Niagen Bioscience, signaling confidence in the company's future prospects.
- The transactions were made under a Rule 10b5-1(c) plan, which suggests a structured, pre-planned investment rather than opportunistic trading.
Future Outlook
The filing does not provide specific forward-looking statements or guidance regarding the company's future performance, beyond the implication of insider confidence from the stock purchase.
Industry Context
Insider purchases, particularly by a Chief Financial Officer, can signal management's belief in the company's valuation or future prospects, potentially indicating a positive outlook within its specific industry segment.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | Transaction made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. | 11/14/2025 | Indicates a pre-arranged, compliant trading strategy, reducing the perception of opportunistic insider trading and aligning management's interests with shareholders. |
Related Party Transactions
- CFO Ozan Pamir's spouse acquired 2,220.443 shares of common stock indirectly at $6.85 per share, which is reported as an indirect beneficial ownership for the CFO.
Stakeholder Impact
- Shareholders may view the CFO's stock purchase as a positive signal of management's belief in the company's value and future performance.
Key Dates
| Date | Description |
|---|---|
| 11/14/2025 | Date of common stock acquisition by CFO Ozan Pamir and his spouse. |
| 11/17/2025 | Date the Form 4 was signed by Attorney-in-Fact. |
Recommendation
holdThe Chief Financial Officer's purchase of company stock, both directly and indirectly through a Rule 10b5-1 plan, signals management's confidence in Niagen Bioscience's future. This insider buying activity is generally viewed positively by the market, suggesting that the stock may be undervalued or has strong future prospects. However, without additional comprehensive financial performance data or strategic updates, a 'hold' recommendation is prudent, encouraging investors to monitor the company's developments while acknowledging this positive insider sentiment.
Keywords
Niagen Bioscience, NAGE, Insider Trading, CFO, Stock Purchase, Form 4, Ozan Pamir, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.